AT2R Agonist Patent EP4506345A1 - Heterocyclic Compounds
Summary
The European Patent Office published patent EP4506345A1 for AT2R agonist heterocyclic compounds assigned to Wuhan Humanwell Innovative Drug Research and Development Center Limited Company. The patent covers therapeutic compounds classified under C07D with applications in cardiovascular (A61P9/00), respiratory (A61P11/00), and renal conditions (A61P13/12). The patent designates 27 European states including major markets such as DE, FR, GB, IT, and ES.
What changed
EPO granted patent EP4506345A1 to Wuhan Humanwell Innovative Drug Research and Development Center Limited Company for AT2R (Angiotensin II Type 2 Receptor) agonist heterocyclic compounds. The patent claims compounds useful for treating cardiovascular, respiratory, and renal conditions based on A61P classifications. Designated states include all major European markets covering AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
For pharmaceutical companies developing AT2R-targeted therapies, this patent may affect freedom-to-operate assessments and licensing negotiations. Competitors in the cardiovascular and renal drug space should review the compound claims to evaluate potential overlap with their own development programs.
What to do next
- Monitor patent database for related applications
- Review freedom-to-operate for AT2R agonist programs
- Assess licensing opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AT2R AGONIST
Publication EP4506345A1 Kind: A1 Apr 01, 2026
Applicants
Wuhan Humanwell Innovative Drug Research and
Development Center Limited Company
Inventors
ZHANG, Xuejun, ZANG, Yang, DING, Xiaohua, GAO, Zhenxing, QIAN, Lina, LI, Qun, YANG, Hui, LI, Lie, YANG, Jun
IPC Classifications
C07D 409/10 20060101AFI20260226BHEP C07D 409/14 20060101ALI20260226BHEP C07D 401/14 20060101ALI20260226BHEP A61K 31/4439 20060101ALI20260226BHEP A61K 31/506 20060101ALI20260226BHEP A61P 9/00 20060101ALI20260226BHEP A61P 11/00 20060101ALI20260226BHEP A61P 13/12 20060101ALI20260226BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.